Sinned
2021-07-29
Like pls
J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant<blockquote>强生承包商计划恢复陷入困境的巴尔的摩工厂的Covid-19疫苗生产</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
7
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":808933154,"tweetId":"808933154","gmtCreate":1627549580378,"gmtModify":1633763904061,"author":{"id":3578452158761953,"idStr":"3578452158761953","authorId":3578452158761953,"authorIdStr":"3578452158761953","name":"Sinned","avatar":"https://static.tigerbbs.com/d90fa3100a053e15ac93aedaaaaefe0c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like pls</p></body></html>","htmlText":"<html><head></head><body><p>Like pls</p></body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/808933154","repostId":1129345317,"repostType":4,"repost":{"id":"1129345317","kind":"news","pubTimestamp":1627549187,"share":"https://www.laohu8.com/m/news/1129345317?lang=zh_CN&edition=full","pubTime":"2021-07-29 16:59","market":"us","language":"en","title":"J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant<blockquote>强生承包商计划恢复陷入困境的巴尔的摩工厂的Covid-19疫苗生产</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129345317","media":"The Wall Street Journal","summary":"Emergent BioSolutions received FDA approval to resume manufacturing after being shut down for contamination","content":"<p>Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.</p><p><blockquote>根据Emergent BioSolutions Inc.的一份声明和《华尔街日报》查阅的FDA信函，该公司计划在获得美国食品和药物管理局的批准后恢复其巴尔的摩工厂的Covid-19疫苗生产。</blockquote></p><p> “We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”</p><p><blockquote>Emergent首席执行官罗伯特·克莱默(Robert Kramer)在周三晚间的一份声明中表示：“在与FDA和我们的制造合作伙伴进行额外审查和合作后，我们很自豪能够恢复批量Covid-19疫苗的生产。”“我们很高兴有机会帮助结束这场全球大流行。”</blockquote></p><p> The plant makes vaccines for Johnson & Johnson.</p><p><blockquote>该工厂为强生公司生产疫苗。</blockquote></p><p> While domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.</p><p><blockquote>尽管近几个月来国内对强生疫苗的需求有所减少，但拜登政府正在寻求将疫苗出口到需要抵御新冠肺炎病毒的国家。</blockquote></p><p> The Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.</p><p><blockquote>在FDA检查员确定巴尔的摩工厂存在严重污染后，该工厂已被关闭。</blockquote></p><p> FDA officials didn’t immediately return calls for comment late Wednesday.</p><p><blockquote>周三晚间，FDA官员没有立即回复评级置评。</blockquote></p><p> In a letter from the FDA to Emergent on Wednesday viewed by the Journal, the federal agency said, “Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing” at the Baltimore plant.</p><p><blockquote>《华尔街日报》看到了FDA周三致Emergent的一封信，该联邦机构表示，“根据我们目前对已实施纠正措施的观察，FDA不反对恢复巴尔的摩工厂的生产”。</blockquote></p><p> One person familiar with the issue said the Emergent plant in Baltimore, once it is operating at full capacity, could make as many as 120 million doses a month. Those finished doses might not be available until this fall, however, the person said.</p><p><blockquote>一位知情人士表示，巴尔的摩的紧急工厂一旦满负荷运转，每月可生产多达1.2亿剂疫苗。不过，该人士表示，这些成品剂量可能要到今年秋天才能上市。</blockquote></p><p> J&J didn’t immediately respond to requests for comment.</p><p><blockquote>强生没有立即回应置评请求。</blockquote></p><p> J&J still has up to 30 million doses that were made earlier at the Baltimore plant left to be potentially cleared for use. J&J’s vaccines are one-dose shots.</p><p><blockquote>强生公司仍有多达3000万剂早先在巴尔的摩工厂生产的疫苗有待批准使用。强生的疫苗是单剂注射。</blockquote></p><p> That vaccine, along with other doses from AstraZeneca PLC, was made at the plant before the FDA action in April leading to the shutdown of the facility. The AstraZeneca vaccine is given as a two-shot regimen.</p><p><blockquote>该疫苗以及阿斯利康公司的其他剂量是在FDA四月份采取行动导致该工厂关闭之前在该工厂生产的。阿斯利康疫苗采用两针方案。</blockquote></p><p> The AstraZeneca vaccine doses that were produced at the facility still haven’t been cleared for use by the FDA.</p><p><blockquote>该工厂生产的阿斯利康疫苗剂量尚未获得FDA批准使用。</blockquote></p><p> The FDA still plans a further, more comprehensive review of the plant after production is under way.</p><p><blockquote>FDA仍计划在生产开始后对该工厂进行进一步、更全面的审查。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant<blockquote>强生承包商计划恢复陷入困境的巴尔的摩工厂的Covid-19疫苗生产</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J Contractor Plans to Resume Covid-19 Vaccine Production at Troubled Baltimore Plant<blockquote>强生承包商计划恢复陷入困境的巴尔的摩工厂的Covid-19疫苗生产</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The Wall Street Journal</strong><span class=\"h-time small\">2021-07-29 16:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.</p><p><blockquote>根据Emergent BioSolutions Inc.的一份声明和《华尔街日报》查阅的FDA信函，该公司计划在获得美国食品和药物管理局的批准后恢复其巴尔的摩工厂的Covid-19疫苗生产。</blockquote></p><p> “We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”</p><p><blockquote>Emergent首席执行官罗伯特·克莱默(Robert Kramer)在周三晚间的一份声明中表示：“在与FDA和我们的制造合作伙伴进行额外审查和合作后，我们很自豪能够恢复批量Covid-19疫苗的生产。”“我们很高兴有机会帮助结束这场全球大流行。”</blockquote></p><p> The plant makes vaccines for Johnson & Johnson.</p><p><blockquote>该工厂为强生公司生产疫苗。</blockquote></p><p> While domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.</p><p><blockquote>尽管近几个月来国内对强生疫苗的需求有所减少，但拜登政府正在寻求将疫苗出口到需要抵御新冠肺炎病毒的国家。</blockquote></p><p> The Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.</p><p><blockquote>在FDA检查员确定巴尔的摩工厂存在严重污染后，该工厂已被关闭。</blockquote></p><p> FDA officials didn’t immediately return calls for comment late Wednesday.</p><p><blockquote>周三晚间，FDA官员没有立即回复评级置评。</blockquote></p><p> In a letter from the FDA to Emergent on Wednesday viewed by the Journal, the federal agency said, “Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing” at the Baltimore plant.</p><p><blockquote>《华尔街日报》看到了FDA周三致Emergent的一封信，该联邦机构表示，“根据我们目前对已实施纠正措施的观察，FDA不反对恢复巴尔的摩工厂的生产”。</blockquote></p><p> One person familiar with the issue said the Emergent plant in Baltimore, once it is operating at full capacity, could make as many as 120 million doses a month. Those finished doses might not be available until this fall, however, the person said.</p><p><blockquote>一位知情人士表示，巴尔的摩的紧急工厂一旦满负荷运转，每月可生产多达1.2亿剂疫苗。不过，该人士表示，这些成品剂量可能要到今年秋天才能上市。</blockquote></p><p> J&J didn’t immediately respond to requests for comment.</p><p><blockquote>强生没有立即回应置评请求。</blockquote></p><p> J&J still has up to 30 million doses that were made earlier at the Baltimore plant left to be potentially cleared for use. J&J’s vaccines are one-dose shots.</p><p><blockquote>强生公司仍有多达3000万剂早先在巴尔的摩工厂生产的疫苗有待批准使用。强生的疫苗是单剂注射。</blockquote></p><p> That vaccine, along with other doses from AstraZeneca PLC, was made at the plant before the FDA action in April leading to the shutdown of the facility. The AstraZeneca vaccine is given as a two-shot regimen.</p><p><blockquote>该疫苗以及阿斯利康公司的其他剂量是在FDA四月份采取行动导致该工厂关闭之前在该工厂生产的。阿斯利康疫苗采用两针方案。</blockquote></p><p> The AstraZeneca vaccine doses that were produced at the facility still haven’t been cleared for use by the FDA.</p><p><blockquote>该工厂生产的阿斯利康疫苗剂量尚未获得FDA批准使用。</blockquote></p><p> The FDA still plans a further, more comprehensive review of the plant after production is under way.</p><p><blockquote>FDA仍计划在生产开始后对该工厂进行进一步、更全面的审查。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=hp_lista_pos3\">The Wall Street Journal</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"JNJ":"强生"},"source_url":"https://www.wsj.com/articles/j-j-contractor-plans-to-resume-covid-19-vaccine-production-at-troubled-baltimore-plant-11627528043?mod=hp_lista_pos3","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129345317","content_text":"Emergent BioSolutions Inc. plans to resume Covid-19 vaccine production at its Baltimore plant after getting the green light from the Food and Drug Administration, according to a statement from the company and an FDA letter reviewed by the Journal.\n“We are proud to be resuming production of bulk Covid-19 vaccine batches following additional reviews and collaboration with FDA and our manufacturing partners,” Emergent CEO Robert Kramer said in a statement late Wednesday. “We are grateful for the opportunity to help bring this global pandemic to an end.”\nThe plant makes vaccines for Johnson & Johnson.\nWhile domestic demand for the Johnson & Johnson shot has dwindled in recent months, the Biden administration is seeking the shots to be exported to countries needing protection against Covid-19.\nThe Baltimore plant had been shut down after FDA inspectors determined there was severe contamination at the plant.\nFDA officials didn’t immediately return calls for comment late Wednesday.\nIn a letter from the FDA to Emergent on Wednesday viewed by the Journal, the federal agency said, “Based upon our current observations of the implemented corrective actions, FDA does not object to the resumption of manufacturing” at the Baltimore plant.\nOne person familiar with the issue said the Emergent plant in Baltimore, once it is operating at full capacity, could make as many as 120 million doses a month. Those finished doses might not be available until this fall, however, the person said.\nJ&J didn’t immediately respond to requests for comment.\nJ&J still has up to 30 million doses that were made earlier at the Baltimore plant left to be potentially cleared for use. J&J’s vaccines are one-dose shots.\nThat vaccine, along with other doses from AstraZeneca PLC, was made at the plant before the FDA action in April leading to the shutdown of the facility. The AstraZeneca vaccine is given as a two-shot regimen.\nThe AstraZeneca vaccine doses that were produced at the facility still haven’t been cleared for use by the FDA.\nThe FDA still plans a further, more comprehensive review of the plant after production is under way.","news_type":1,"symbols_score_info":{"JNJ":0.9}},"isVote":1,"tweetType":1,"viewCount":279,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/808933154"}
精彩评论